The pandemic has been a major disruptor to the medtech industry but medtech M&A is and remains hot. We’ve seen more deals made in 2021 than were made through all of 2020. To be specific, the number of deals done thru just the first six months of this year is 30+% above the total number of deals done in all of 2020. While the pace is expected to slow in the second half of the year, the number of companies looking to partner and acquire is significant and it is also diverse. Recent transactions range from dental to diagnostic, from surgical to wearables and to cardiology. As many companies find themselves with deep cash reserves and others are generating large COVID related sales, expectations for more activity remains high. Join us and our engaging and dynamic panel for a discussion of current MedTech finance, business development and M&A activity.